SHIPPED: Between 4-14-58 and 10-10-58, from Kansas City, Kans., by Curts Laboratories.

LABEL IN PART: (Jar and drum) "Curts Hexadin with Dextrose 50% For oral administration in iodine deficiencies and in cases of actinomycosis in soft tissues that do not require surgery. Organic iodine compound . . . 5% (Hexamethylenetetramine tetraiodide 75.5% iodine) * * * Directions * * * Cattle and Horses * * * Sheep and Swine."; (jar) "Curts Arsan Powder for swine dysentery or enteritis and/or a stomachic Sodium arsanilate . . . 26% * * * Sodium phenolsulfonate, Iron pyrophosphate, Copper sulfate, Boric acid, Cobalt sulfate"; and (jar) "Curts Weatol Fish liver oil with alpha tocopherol acetate For oral administration as supplement in deficiencies of vitamins A, D and E. Daily dose Large animals * * * Small animals."

ACCOMPANYING LABELING: Catalog entitled "Curts 1958 Products and Prices" and pamphlet entitled "Feature Drug Items Produced by Curts."

LIBELED: 4-9-59, Dist. Nebr.

CHARGE: 502(a)—(Hexadin) when shipped, the labeling, namely, the abovedescribed catalog and pamphlet accompanying the article, contained false and misleading representations that the article was an adequate and effective treatment for the prevention of necrotic stomatitis and pneumonia, liver abscesses, calf diphtheria, keratitis, sterility and actinobacillosis in cattle, horses, sheep, and swine; (Weatol) the labeling, namely, the jar label and the above-described catalog and pamphlet accompanying the article, contained false and misleading representations that the article was an adequate and effective treatment for overcoming incidence of stillbirth and deformed offspring, and for increasing fertility of large and small animals; and the labeling of the Weatol also was misleading since it failed to reveal the amounts of vitamins A, D, and E present in the article, and also since the name "Weatol" suggested that the article contained a wheat germ oil base, when, in fact, it was labeled elsewhere as a fish liver oil base; and 502(f)(2)—(Arsan Powder) the article contained sodium arsanilate, and its labeling failed to warn that administration of the drug should be discontinued five days before slaughtering for human consumption to allow for elimination of the drug from the edible tissue.

DISPOSITION: 4-30-59. Default—destruction.

DRUGS AND DEVICES ACTIONABLE BECAUSE OF DEVIATION FROM OFFICIAL OR OWN STANDARDS*

5909. Desarin tablets. (F.D.C. No. 40575. S. Nos. 72-987/8 M.)

QUANTITY: 128 100-tablet btls. and 26 100-tablet btls. at Salt Lake City, Utah. Shipped: 12-31-56 and 5-29-57, from St. Louis, Mo., by Victor M. Hermelin & Co.

LABEL IN PART: (128-tablet lot) "Desarin * * * Estrogenic Substance * * * Each tablet contains .625 mg. of estrogens in their naturally occurring water-soluble conjugated form * * * Control No. 11-66"; or (26-tablet lot) "Each tablet contains 1.25 mg. of estrogens in their naturally occurring water-soluble conjugated form * * * Control No. 5-66."

RESULTS OF INVESTIGATION: Analysis showed that the 128-tablet lot of the article contained 0.29 mg. of sodium estrone sulfate per tablet; and the 26-tablet lot of the article contained .91 mg. of sodium estrone sulfate per tablet.

^{*}See also No. 5907.

LIBELED: 9-13-57, Dist. Utah.

CHARGE: 501(c)—when shipped, the strength of the article differed from that which it purported and was represented to possess; and 502(a)—the label statements "Each tablet contains .625 mg. [or 1.25 mg.] of estrogens in their naturally occurring water-soluble conjugated form" were false and misleading.

DISPOSITION: 12-27-57. Default—destruction.

5910. Conjugated estrogen tablets. (F.D.C. No. 42755. S. No. 28-470 P.)

QUANTITY: 1 drum containing 20,000 tablets at Houston, Tex.

Shipped: 11-25-58, from Philadelphia, Pa., by Lustgarten Laboratories, Inc.

RESULTS OF INVESTIGATION: Analysis showed that the total estrogen content per tablet corresponded to not more than 0.70 milligram of sodium estrone sulfate.

Libeled: 12-31-58, S. Dist. Tex.

CHARGE: 501(c)—when shipped, the strength of the article differed from that which it purported and was represented to possess, namely, that each tablet contained an amount of estrogens equivalent to 1.25 milligrams of sodium estrone sulfate; and 502(a)—when shipped and while held for sale, the label statement "Conjugated Estrogens 1.25 Mgm. * * * expressed in terms of an equivalent quantity of Sodium Estrone Sulfate" was false and misleading.

DISPOSITION: 2-20-59. Default—destruction.

5911. Dexobese timed disintegration capsules. (F.D.C. No. 42781. S. No. 34-900 P.)

QUANTITY: 9 500-capsule btls., 24 100-capsule btls., and 71 30-capsule btls. at Philadelphia, Pa.

SHIPPED: 10-10-58, from Rensselaer, N.Y., by Delmar Pharmacal Corp.

RESULTS OF INVESTIGATION: The article was shipped in bulk as described above and after its receipt by the consignee at Philadelphia, Pa., was repackaged in the above-mentioned bottles.

Analysis showed that the article contained 80.7 percent of the 15 mgs. of amphetamine sulfate per capsule which it was represented to have.

Libeled: 1-9-59, E. Dist. Pa.

CHARGE: 501(c)—when shipped, the strength of the article differed from that which it purported and was represented to possess, since the article contained less than the declared amount of amphetamine sulfate.

DISPOSITION: 2-4-59. Default—destruction.

5912. Para Dex Fifteen capsules and Para Barb 3 capsules. (F.D.C. No. 42796. S. Nos. 41-592/3 P.)

QUANTITY: 57 100-capsule btls., and 11 250-capsule btls., of Para Dex Fifteen capsules, and 97 100-capsule btls., of Para Barb 3 capsules, at Salem, Oreg.

SHIPPED: 10-6-58, from Rensselaer, N.Y., by Delmar Pharmacal Corp.

LABEL IN PART: (Btl.) "Para Dex Fifteen Capsules Three Releases * * * Each Para Dex Fifteen Capsule contains 15 mg. of Dextro-Amphetamine Sulfate to release uniformly over a period of six to ten hours," and "Para Barb 3 Capsules * * * Each Para Barb 3 Capsule contains: Phenobarbital 100 mg. A brand of time disintegration capsule."